利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.05 秒)

    MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA
    3.
    发明申请
    MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA 有权
    GLAUCOMA的治疗或预防药物组合物

    公开(公告)号：US20120190852A1

    公开(公告)日：2012-07-26

    申请号：US13260946

    申请日：2010-03-30

    申请人： Masahiko Hagihara ,  Kenji Yoneda ,  Eiji Okanari ,  Manabu Shigetomi

    发明人： Masahiko Hagihara ,  Kenji Yoneda ,  Eiji Okanari ,  Manabu Shigetomi

    IPC分类号： C07D401/14 ,  C07D409/14 ,  C07D401/12 ,  C07D405/14 ,  C07D417/14 ,  C07D417/12

    CPC分类号： A61K31/506 ,  A61K31/44 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/501 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/12 ,  C07D417/14

    摘要： The present invention is to provide a medical composition for the treatment or prophylaxis of glaucoma which comprises a pyridylaminoacetic acid compound represented by the formula (1): wherein R1, R2 and R3 each independently represent a hydrogen atom or C1-C6 alkyl group, Y represents a bicyclic heteroaromatic ring group which may be substituted by a group(s) selected from the group consisting of a halogen atom, C1-C6 alkyl group, halogeno C1-C6 alkyl group, C1-C6 alkoxyl group, halogeno C1-C6 alkoxyl group and C1-C6 alkylthio group or a group -Q1-Q2 wherein Q1 represents an arylene group or 5- to 6-membered heteroarylene group, Q2 represents an aromatic group or a 5- to 6-membered ring heterocyclic group each of which may be substituted by a group(s) selected from the group consisting of a halogen atom, hydroxyl group, C1-C6 alkyl group, halogeno C1-C6 alkyl group, C1-C6 alkoxyl group and halogeno C1-C6 alkoxyl group, Z represents an aromatic group or a 5- to 6-membered heteroaromatic ring group each of which may be substituted by a group(s) selected from the group consisting of a halogen atom, C1-C6 alkyl group, halogeno C1-C6 alkyl group, C1-C6 alkoxyl group and halogeno C1-C6 alkoxyl group, or a pharmaceutically acceptable salt thereof as an effective ingredient.

    摘要翻译： 本发明提供一种治疗或预​​防青光眼的药物组合物，其包含式（1）表示的吡啶基氨基乙酸化合物：其中R1，R2和R3各自独立地表示氢原子或C1-C6烷基，Y 表示可以被选自卤素原子，C 1 -C 6烷基，卤代C 1 -C 6烷基，C 1 -C 6烷氧基，卤代C 1 -C 6烷氧基，卤代C 1 -C 6烷氧基， 基团和C 1 -C 6烷硫基或基团-Q 1 -Q 2，其中Q 1表示亚芳基或5-至6-元亚杂芳基，Q 2表示芳族基团或5至6元环杂环基，其各自可以 被选自卤素原子，羟基，C 1 -C 6烷基，卤代C 1 -C 6烷基，C 1 -C 6烷氧基和卤代C 1 -C 6烷氧基的基团取代，Z表示 芳族基团或5-至6-元杂芳族化合物 可以被选自卤素原子，C 1 -C 6烷基，卤代C 1 -C 6烷基，C 1 -C 6烷氧基和卤代C 1 -C 6烷氧基的基团取代的环氧基 ，或其药学上可接受的盐作为有效成分。

    Pyrrolopyridazinone Compound
    7.
    发明申请
    Pyrrolopyridazinone Compound 失效

    公开(公告)号：US20090036453A1

    公开(公告)日：2009-02-05

    申请号：US12087864

    申请日：2007-01-16

    申请人： Masahiko Hagihara ,  Masayuki Tanaka ,  Tetsushi Katsube ,  Makoto Okudo ,  Noriaki Iwase ,  Manabu Shigetomi ,  Tomoko Kanda ,  Takayuki Nakanishi

    发明人： Masahiko Hagihara ,  Masayuki Tanaka ,  Tetsushi Katsube ,  Makoto Okudo ,  Noriaki Iwase ,  Manabu Shigetomi ,  Tomoko Kanda ,  Takayuki Nakanishi

    IPC分类号： A61K31/5025 ,  C07D487/02 ,  A61P11/00 ,  A61P9/00 ,  A61P37/00

    CPC分类号： C07D487/04

    摘要： The present invention discloses a pyrrolopyridazinone compound represented by the formula (1): wherein R1 represents C1-C2 alkyl group or halogeno C1-C2 alkyl group, R2 repersents C3-C5 cycloalkyl group, (C3-C5 cycloalkyl)C1-C2 alkyl group or C1-C3 alkyl group, R3 represents hydrogen atom, or methylene group or cis-vinylene group for forming substituted oxygen-containing hetero ring in combination with group —O—R2, R4 represents hydrogen atom, halogen atom, C1-C8 alkyl group, C2-C6 alkenyl group, C2-C6 alkynyl group, hydroxy C3-C6 alkenyl group, hydroxy C3-C6 alkynyl group, C1-C6 alkyl group substituted by substituent(s) selected from Substituent group (a), C3-C6 cycloalkyl group which may be substituted by substituent(s) selected from Substituent group (b), “C1-C3 alkyl group which is substituted by C3-C6 cycloalkyl group which may be substituted by substituent(s) selected from Substituent group (b), and which may be substituted by a hydroxy group”, an aromatic ring group or heteroaromatic ring group each of which may be substituted by a substituent(s) selected from Substituent group (c) or “C1-C2 alkyl group which is substituted by aromatic ring group or heteroaromatic ring group each of which may be substituted by group(s) selected from Substituent group (c), and which may be substituted by a hydroxy group”, Substituent group (a) represents a halogen atom, hydroxy group, cyano group, carboxy group, C1-C5 alkoxy group, halogeno C1-C4 alkoxy group, C3-C6 cycloalkoxy group, (C3-C6 cycloalkyl)C1-C2 alkoxy group, C1-C4 alkoxycarbonyl group, C2-C4 alkanoyl group, C2-C4 alkanoyloxy group or C1-C4 alkyl-substituted amino group, Substituent group (b) represents a hydroxy group or a halogen atom, Substituent group (c) represents a halogen atom, a hydroxy group, a cyano group, a nitro group, a carboxy group, C1-C5 alkoxy group, C1-C4 alkoxycarbonyl group, C2-C4 alkanoyloxy group, C1-C4 alkyl-substituted amino group or a C1-C4 alkyl group which may be substituted by a substituent(s) selected from the group consisting of (a halogen atom, a hydroxy group and a carboxy group), or a pharmaceutically acceptable salt thereof.